References
- Punga AR, Maddison P, Heckmann JM, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176–188. doi: 10.1016/S1474-4422(21)00297-0
- Howard JF Clinical overview of MG. Myasthenia gravis Foundation of America. [cited 2023 Aug 30]. Available from: https://myasthenia.org/Professionals/Clinical-Overview-of-MG
- Bril V, Szczudlik A, Vaitkus A, et al. Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis. Neurology. 2023;100(7):671–682. doi: 10.1212/WNL.0000000000201501
- Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113–124. doi: 10.1038/s41582-018-0110-z
- Fichtner ML, Jiang R, Bourke A, et al. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol. 2020;11:11. doi: 10.3389/fimmu.2020.00776
- Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018;10(7):1111–1130. doi: 10.1080/19420862.2018.1505464
- Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691–701. doi: 10.1080/1744666X.2022.2082946
- Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:175628642199738. doi: 10.1177/1756286421997381
- Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Trans Med. 2017;9(414). doi: 10.1126/scitranslmed.aan1208
- Johnson S, Katyal N, Narula N, et al. Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis. Med Sci Monit. 2021;27: doi: 10.12659/MSM.933296
- Guptill JT, Juel VC, Massey JM, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49(7):472–479. doi: 10.1080/08916934.2016.1214823
- Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4(10):557–567. doi: 10.1038/ncpneuro0901
- UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan. Brussels Belgium: UCB New Press Release; [cited 2023 Sep 25-28]. Available from: https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-approval-of-RYSTIGGOR-rozanolixizumab-and-ZILBRYSQR-zilucoplan-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-in-Japan
- Nair SS, Jacob S. Novel immunotherapies for myasthenia gravis. Immunotargets Ther. 2023;12:25–45. doi: 10.2147/ITT.S377056
- Karam C, Murai H, Smilowski M, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–536. doi: 10.1016/S1474-4422(21)00159-9
- FDA approves New treatment for myasthenia gravis. FDA News Release. 2021 Dec 17 [cited 2023 Jul 20]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis
- Zhu LN, Hou HM, Wang S, et al. FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res. 2023;18(8):1637–1644. doi: 10.4103/1673-5374.363824
- Vaccaro C, Zhou J, Ober RJ, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nature Biotechnol. 2005;23(10):1283–1288. doi: 10.1038/nbt1143
- Rozanolixizumab-noli. American Journal Of Health-System Pharmacy. [cited 2023 Sep 13-20]. Available from: https://doi-org.myaccess.library.utoronto.ca/10.1093/ajhp/zxad208
- Highlights of prescribing information: Rozanolixizumab-noli. US Food & Drug Administration Access data. 2023 [cited 2023 Sep 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf
- Bril V, Benatar M, Andersen H, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96(6):e853–e865. doi: 10.1212/WNL.0000000000011108
- Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383–394. Erratum in: Lancet Neurol. Oct 2023;22(10):e11. PMID: 37059507. doi: 10.1016/S1474-4422(23)00077-7
- A randomized, open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis, ClinicalTrials.Gov identifier: NCT04124965. [Updated 2023 Sep 5; cited 2023 Sep 5-15]. Available from: https://clinicaltrials.gov/study/NCT04124965
- An open-Label extension study to evaluate rozanolixizumab in study participants with generalized myasthenia gravis. ClinicalTrials.gov identifier: NCT04650854. [Updated 2023 Sep 15; cited 2023 Sep 15-21]. Available from: https://clinicaltrials.gov/study/NCT04650854
- An Open-Label, crossover study to evaluate rozanolixizumab self-administration by study participants with generalized myasthenia gravis. ClinicalTrials.Gov identifier: NCT05681715. [Updated 2023 Sep 25; cited 2023 Sep 25]. Available from: https://clinicaltrials.gov/study/NCT05681715
- Querol L, de Seze J, Dysgaard T, et al. Rozanolixizumab in chronic inflammatory demyelinating polyradiculoneuropathy: randomized subject-/Investigator-blind placebo-controlled Phase 2a trial. In: peripheral nerve society annual meeting 2022 abstract supplement. J Peripheral Nerv Syst. 2022 Jul;27(S3):S4–S183. Abstract: 66b
- A study to evaluate the efficacy, safety, and tolerability of rozanolixizumab in adult study participants with PersistRent or Chronic Primary immune Thrombocytopenia (ITP) (myOpportunity1). ClinicalTrials.Gov Identifier: NCT04200456. [Updated 2023 Aug 08; cited 2023 Sep 20]. Available from: https://clinicaltrials.gov/study/NCT04200456
- A randomized, double-blind, placebo-controlled, multicenter, Phase 3, pivotal study with an open-label extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with Myelin Oligodendrocyte Glycoprotein (MOG) antibody-associated disease (MOG-AD). ClinicalTrials.Gov Identifier: NCT05063162. [Updated 2023 Aug 21; cited 2023 Sep 16]. Available from: https://clinicaltrials.gov/study/NCT05063162
- Dubey D, Titulaer MJ, Koul AD, et al. The first randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of an FcRn inhibitor, rozanolixizumab, in patients with leucine-rich glioma inactivated 1 autoimmune encephalitis. In: 2022 AAN Summer Conference; San Francisco and Virtual. 2022 Jul 16. Abstract. p. 2–009.
- A randomized, double-blind, placebo-controlled, multicenter, Phase 2A, proof-of-concept study to evaluate the efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome. ClinicalTrials.Gov Identifier: NCT05643794. [Updated 2023 Sep 22; cited 2023 Sep 22-25]. Available from: https://clinicaltrials.gov/study/NCT05643794
- UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis. Brussels Belgium: UCB News Press Release; 2023 June 27 [cited 2023 July 20]. Available from: https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-US-FDA-approval-of-RYSTIGGOR-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis
- UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority review. Brussels Belgium: UCB News press release; 2023 Jan 6 [cited 2023 Sep 16]. Available from: https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-rozanolixizumab-BLA-for-the-treatment-of-generalized-myasthenia-gravis-filed-with-US-FDA-and-designated-for-Priority-Review#:~:text=Brussels%20(Belgium)%206%20Jan%202023,that%20the%20Agency%20has%20granted